Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

PAVmed (PAVM) Income from Continuing Operations (2022 - 2025)

Historic Income from Continuing Operations for PAVmed (PAVM) over the last 4 years, with Q3 2025 value amounting to -$6.0 million.

  • PAVmed's Income from Continuing Operations changed N/A to -$6.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 million, marking a year-over-year change of. This contributed to the annual value of $28.4 million for FY2024, which is 13586.41% up from last year.
  • According to the latest figures from Q3 2025, PAVmed's Income from Continuing Operations is -$6.0 million.
  • In the past 5 years, PAVmed's Income from Continuing Operations registered a high of $18.6 million during Q1 2025, and its lowest value of -$29.9 million during Q3 2022.
  • Moreover, its 4-year median value for Income from Continuing Operations was -$18.2 million (2023), whereas its average is -$15.3 million.
  • Its Income from Continuing Operations has fluctuated over the past 5 years, first tumbled by 1314.62% in 2023, then surged by 20059.96% in 2025.
  • Over the past 4 years, PAVmed's Income from Continuing Operations (Quarter) stood at -$24.6 million in 2022, then rose by 29.16% to -$17.4 million in 2023, then surged by 106.56% to $1.1 million in 2024, then tumbled by 626.36% to -$6.0 million in 2025.
  • Its Income from Continuing Operations was -$6.0 million in Q3 2025, compared to -$12.3 million in Q2 2025 and $18.6 million in Q1 2025.